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PRS17
COSTS TO TREAT COMMUNITY-ACQUIRED PNEUMONIA EPISODES IN 
US ADULTS AGED 50 YEARS AND OLDER BY AGE AND RISK
Sato R1, Strutton D1, Phillips B2, Grifﬁths S2
1Pﬁzer Inc., Collegeville, PA, USA, 2Ingenix Consulting, Eden Prairie, MN, USA
OBJECTIVES: This retrospective study assessed the costs to treat community-acquired 
pneumonia (CAP) episodes by risk, age, and hospitalization in US adults aged ≥50. 
METHODS: A multi-payer administrative claims database containing over 2 million 
lives aged ≥50 (800,000+ for aged ≥65) was used to identify CAP episodes between 
July 2006 and June 2007. An episode of pneumonia was deﬁned as the period between 
the ﬁrst and last pneumonia ICD-9 code with a chest x-ray claim. Episodes were also 
required to have a pre-post episode period free of pneumonia claims of at least 90 
days. Patients who were hospitalized or institutionalized in the 2 weeks prior to the 
start of the episode were excluded. Episode costs included all-cause medical and 
pharmacy costs. Results were stratiﬁed by age, risk (high: immunocompromised; 
moderate: immunocompetent with chronic medical condition; low: immunocompetent 
without chronic medical condition), and whether or not an episode included hospi-
talization. RESULTS: There were 21,086 CAP episodes among individuals aged ≥50 
with 29% resulting in hospitalization. Among those who were hospitalized, 48%, 
37%, and 15% were from the low, moderate, and high risk groups, respectively. The 
mean cost of a hospitalized CAP episode for the low, moderate, and high risk groups 
was $14,233, $19,470, and $ 27,032, respectively. For ages 50–64 years old, the mean 
cost of a hospitalized episode was $16,606 compared with $18,493 for age ≥65 years 
old. Costs of outpatient CAP episodes were substantially lower with a mean of $1047, 
$1241, and $2055 for low, moderate, and high risk groups, respectively. CONCLU-
SIONS: The cost to treat CAP which requires hospitalization is high regardless of risk 
category or age. Almost half of the hospitalized CAP patients do not appear to have 
traditional risk factors for pneumonia suggesting the need for better treatment and 
prevention strategies.
PRS18
ASSESSMENT OF THE CLINICAL AND ECONOMIC IMPACT OF AIR 
LEAKS DURING POST-OPERATIVE PULMONARY SURGERY
Nagel MP1, Gemmen E2, Smith BF3, Doyle J4, Garvert W2
1Neomend, Inc., Irvine, CA, USA, 2Quintiles, Falls Church, VA, USA, 3Quintiles Consulting, 
Hawthorne, NY, USA, 4Quintiles Global Consulting, Hawthorne, NY, USA
OBJECTIVES: Estimate the clinical and economic impact to U.S. hospitals of air leaks 
during post-operative pulmonary surgery. METHODS: Analysis of the 2006 Nation-
wide Inpatient Sample (NIS) hospital database. ICD-9 diagnosis and procedure codes 
were identiﬁed by expert medical opinion and a certiﬁed coder. For all stays with pul-
monary surgery, length of stay (LOS), total charges, and in-hospital mortality rates 
were compared between those stays including an air leak vs. those stays without an air 
leak. Unadjusted results were calculated using descriptive statistics (mean, median, 
frequencies, etc.) Adjusted results were calculated using multivariate regression analysis 
while controlling for age and gender. RESULTS: There were a total of 77,117 hospital 
inpatient stays with pulmonary surgery in 2006, 11,774 (15.3%) of which included air 
leak and 65,342 (84.7%) of which did not. Patients with pulmonary surgery stays 
including air leak were older than those patients without air leak (mean age = 61.5 yrs 
vs. 60.2 yrs; p = 0.0002), had a longer LOS on average (10.9 days vs. 7.4 days; p < 
0.0001), had more total charges ($67,554 vs. $52,550; p < 0.0001) and were more 
likely to die during their stay (2.87% vs. 2.25%; p = 0.0578). After adjusting for dif-
ferences in age and gender between the two groups, the incremental LOS, total charges 
and absolute risk of in-hospital mortality due to the presence of air leak is 3.54 days, 
$14,926 and +12.20%, respectively. The total nationwide additional economic impact 
of having an air leak after pulmonary surgery, estimated by applying patient level 
adjusted charges to the incidence of air leak, is $175.7 million. CONCLUSIONS: The 
clinical and economic impact to U.S. hospitals of air leaks during or following major 
pulmonary surgery is signiﬁcant. The reduction or elimination of these air leaks could 
save considerable hospital resources, payer dollars and patient lives.
PRS20
THE ECONOMIC BURDEN OF CHRONIC DISEASES IN ADULT US 
WORKERS IN TERMS OF MEDICAL EXPENDITURE AND LOST 
PRODUCTIVITY COSTS
Kwon JW1, Choi IS1, Qureshi Z1, Suh K2, McGuire M1, Kim CM3
1Rutgers University School of Pharmacy, Piscataway, NJ, USA, 2Rutgers University, East 
Brunswick, NJ, USA, 3Catholic University School of Medicine, Seoul, South Korea
OBJECTIVES: To estimate annual medical expenditure (ME) and lost productivity 
cost (PC) attributable to chronic diseases in working U.S. adults. METHODS: A 
cross-sectional design, using the 2003–2006 Medical Expenditure Panel Survey data 
was employed. We identiﬁed working adults who were 18–64 years old and classiﬁed 
them as having chronic diseases (arthritis, asthma, hypertension, hypercholesterolemia, 
or diabetes) or not. We excluded patients with malignancy, kidney dialysis, immuno-
deﬁciency, pregnancy, or BMI < 18.5. MEs were estimated using a generalized linear 
model with log link function and gamma distribution. PC was calculated based on 
missed working days due to illness and average hourly wage, using a two-part model. 
Costs attributable to chronic diseases were estimated by differences between actual 
and expected cost in patients with chronic diseases, using a distribution of covariates 
obtained from all patients. Treatment costs were converted to 2008 U.S. dollars using 
price indices. RESULTS: Among the identiﬁed 54,843 working adults, a third (34%) 
had at least one of ﬁve chronic diseases. Patients with two or ≥ three chronic diseases 
accounted for 8.5% and 3.7%, respectively. The average ME in patients with chronic 
diseases was signiﬁcantly higher than individuals without those diseases ($2997; 
95%CI = $2865–$3129 vs. $1021; 95%CI = $911–$1130). The average PC in these 
patients showed a similar trend ($481; 95%CI = $455–$507 vs. $236; 95%CI = 
$219–$253). Excess ME attributable to chronic diseases were estimated at $1605 
(95%CI:$1501–$1710) and excess PC at $173 (95%CI $172–$ 174). ME and PC 
increased with an increase in concurrent chronic diseases, respectively. Among the 
chronic diseases, arthritis and diabetes were the largest contributors to additional 
economic burden. CONCLUSIONS: The presence of chronic diseases in working 
patients resulted in signiﬁcantly higher ME and PC. The results highlight the additional 
economic burden attributable to chronic diseases in the working population and the 
need to allocate resources toward better management strategies for these diseases.
PRS21
ANALYSIS OF CLINICAL EFFICACY AND DIRECT COSTS OF THE 
SPECIFIC IMMUNOTHERAPY IN POLAND–A THREE-YEAR 
RETROSPECTIVE STUDY
Jahnz-Roozyk KM, Targowski T, Przekora P
Military Institute of the Health Service, Warsaw, Poland
OBJECTIVES: The aim of the study was 1) To evaluate the clinical efﬁcacy of speciﬁc 
allergen immunotherapy (SIT), and 2) To assess which patients have most beneﬁts 
from SIT METHODS: The investigations were carried out on the group of 120 
patients (37 children, and 83 adults). The effects of SIT (subcutaneous, perennial, 
Allergopharma, Germany) were evaluated through the means of the rate of reduction 
of allergic symptoms and utilization of anti-allergic symptomatic drugs. The cost of 
drugs was based on the catalogue price lists. Linear regression models have been used 
for assessment of relationship between reduction of intensity of allergic symptoms and 
savings on symptomatic drugs. RESULTS: After 3 years of the SIT mean percentage 
of reduction of allergic symptoms and utilization of symptomatic drugs was about 
80%. Mean savings on symptomatic treatment (PLN/EUR) {1EUR = 4PLN in 2009} 
were 664.5/166,1 (95%CI: 517.4/129.4−811.7/202.9) from social perspective and 
274.3/68.5 (95%CI: 227.4/56.8−321.2/80.3) from the patient’s perspective. The 
largest clinical improvement of allergic symptoms was observed in patients with 
combination of seasonal allergy (r = 0.25; p = 0.01), allergic rhinitis (r = 0.21; p = 
0.02) and bronchial asthma (r = 0.34; p = 0.0002). Presence of bronchial asthma was 
also signiﬁcantly related to the volume of savings on anti-allergic symptomatic treat-
ment from the social (r = 0.37, p = 0.0002) and patient’s (r = 0, 31; p = 0.003) per-
spectives. CONCLUSIONS: SIT signiﬁcantly decreases symptoms and anti-allergic 
drug intake. From social and patient’s perspective, SIT in patients with asthma essen-
tially reduces costs of symptom-relieving drugs. It can be a premise to consider to 
increase a level of reimbursement of SIT in this group of patients in Poland.
PRS22
COST-BENEFIT ANALYSIS OF VARENICLINE VS. EXISTING SMOKING 
CESSATION STRATEGIES IN PREGNANT WOMEN
Barnard M, Price J
The University of Mississippi, University, MS, USA
OBJECTIVES: Despite well documented harm to both the mother and the fetus, 
maternal smoking during pregnancy continues to hover above 15%. While pharma-
ceutical interventions have been shown to be cost-effective in the general population, 
current treatment options are poorly understood, insufﬁciently utilized and insufﬁ-
ciently effective in pregnant women. No data regarding safety or efﬁcacy of varenicline 
has been reported for this population. To determine if clinical study of varenicline for 
pregnant smokers is warranted, a cost-beneﬁt analysis of varenicline compared to 
existing treatment modalities will determine if there is likely any cost-beneﬁt associated 
with varenicline use in this population. METHODS: A decision analysis model was 
developed to evaluate from the payer’s perspective the optimal treatment from the 
standpoint of cost versus beneﬁt of potential treatment with varenicline compared to 
other smoking cessation treatment options in pregnant smokers. Outcomes included 
smoking cessation rates, cost of maternal and infant outcomes associated with 
smoking, and treatment costs. A sensitivity analysis was performed to determine the 
effects of variations in the success of treatment with varenicline. RESULTS: The 
analysis showed that buproprion is more cost-beneﬁcial than the other treatments, 
with a net beneﬁt of $1086 per pregnant smoker who attempts to quit, compared with 
$316 for usual care, $550 for motivational interviewing, $830 for NRT, and $938 
for varenicline. Sensitivity analyses indicate that at a 25% cessation rate, varenicline 
becomes the most cost-beneﬁcial treatment option. CONCLUSIONS: From a payer’s 
perspective and current knowledge of cessation rates with pregnant smokers, bupro-
prion is more cost-beneﬁcial smoking cessation intervention in pregnant women than 
existing treatment options. If pregnant smokers are more successful than non-pregnant 
smokers at quitting on varenicline, as they are with the other cessation treatments, it 
is likely that varenicline is the most cost-beneﬁcial treatment and may warrant addi-
tional study in this population.
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THE POTENTIAL COST IMPACT OF USING A PEG HYDROGEL 
SEALANT TO PREVENT AIR LEAKS AFTER LUNG RESECTION SURGERY 
IN THE UNITED KINGDOM
Minshall ME1, Larkin MJ2, Ott M3
1Covidien, North Haven, CT, USA, 2PRMA Consulting, Fleet, UK, 3Covidien, Zurich, 
Switzerland
OBJECTIVES: Persistent air leaks after lung resection surgery often lead to increased 
complications including longer length of hospital stay and subsequent treatment costs. 
